The Peterson Health Technology Institute (PHTI) published a systematic literature review on Sept. 9, 2026, that found no consistent evidence that virtual chronic kidney disease (CKD) platforms slow kidney function decline compared to routine care. The review encompassed 34 unique clinical studies and multi-year data from CMS's Kidney Care Choices model.^[1] PHTI reported that five of the eight evaluated companies-DaVita Integrated Kidney Care, Evergreen Nephrology, Kidneylink, Monogram Health, and Somatus-produced zero peer-reviewed clinical evidence meeting review standards, despite each raising over $100 million.^[2] The read here is that the review challenges the clinical rationale for a category of digital health companies that have attracted substantial venture capital. The absence of published evidence from five well-funded firms suggests the field has prioritized market expansion over generating the kind of data that would support claims of slowing disease progression. A separate meta-analysis published in Medicine on Sept. 1, 2026, examined vitamin D deficiency and CKD progression. The pooled analysis of 10 studies suggested vitamin D deficiency was associated with 33% higher odds of CKD progression (OR = 1.33, 95% CI: 1.06-1.67; P =.019), though between-study heterogeneity was considerable (I² = 98.2%).^[4] The PHTI review authors state that the absence of larger clinical trials and reliance on low-level evidence substantially limit current interpretations.^[3] The review does not name specific companies beyond those listed, and PHTI did not comment on whether any of the five firms have studies underway.